CSIMarket
 
Bioplus Acquisition Corp   (BIOS)
Other Ticker:  
 
 
Price: $10.8000 $-0.02 -0.189%
Day's High: $10.8 Week Perf: -0.28 %
Day's Low: $ 10.79 30 Day Perf: 0.37 %
Volume (M): 4 52 Wk High: $ 11.68
Volume (M$): $ 42 52 Wk Avg: $10.61
Open: $10.79 52 Wk Low: $10.42



 Market Capitalization (Millions $) 221
 Shares Outstanding (Millions) 21
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 6
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Bioplus Acquisition Corp
Bioplus Acquisition Corp is a special purpose acquisition company (SPAC) formed for the purpose of merging with or acquiring a company operating in the biotechnology or pharmaceutical sector. SPACs like Bioplus raise capital through an initial public offering (IPO) and then use those funds to acquire an existing company. As a result, the acquired company becomes publicly traded through the merger with the SPAC. Bioplus focuses specifically on the biotechnology and pharmaceutical industry, indicating its interest in driving innovation and advancements in healthcare through strategic acquisitions.


   Company Address: 260 Madison Avenue New York 10026 NY
   Company Phone Number: 287-4092   Stock Exchange / Ticker: NASDAQ BIOS
   BIOS is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Bioplus Acquisition Corp

Bioplus Acquisition Corp's Healthcare Facilities Business Sees Marginal Decline in Recent Fiscal Period

During the past 5 days, Bioplus Acquisition Corp shares took a slight dip of -0.19%. While this may not be significant, it brings the year-to-date performance to a noteworthy 4.09%. Additionally, the shares of the company are currently 4.9% below their 52-week high.
Observers in the Healthcare Facilities sector are eagerly awaiting the second-quarter results of Bioplus Acquisition Corp in 2023. The company has reported an operating shortfall of $-1.278991 million for this quarter, indicating that it has not generated any revenue during the April to June 30, 2023 reporting period.

Bioplus Acquisition Corp

Bioplus Acquisition Corp Delivers Solid Financial Performances Amidst Challenging Times, Reports Operating Loss of $-0.275274 Million

Bioplus Acquisition Corp is a leading healthcare facilities company that has been making significant strides in the healthcare industry. The company has been able to demonstrate solid financial performances, which are essential in establishing the trust and confidence of shareholders. The investors have been optimistic about the company, as they have not anticipated any significant moderations in the company's revenue during the earnings season of January to March 31, 2023.
However, the company has experienced an operating loss that amounted to $-0.275274 million in the matching time. This can be attributed to the challenges faced by the healthcare industry in recent years, including the COVID-19 pandemic, which has taken a toll on the financial performance of companies in the sector. Nonetheless, Bioplus Acquisition Corp is still viewed positively as it has been able to conduct business more economically than it did in the same period a year before.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com